Body Vision Medical, a leader in AI-powered intraoperative imaging, is pleased to announce that its LungVision advanced imaging platform has received Pre-Market Approval from Singapore’s Health Sciences Authority (HSA). This clearance enables full commercialization of LungVision in Singapore and represents a significant milestone in the company’s ongoing mission to improve early and accurate diagnosis of lung cancer worldwide.

Lung cancer is a significant health concern in Singapore, ranking as the second most common cancer in men and the third most common in women. Over a five-year period (2018-2022), approximately 9,000 cases were diagnosed. According to the Singapore Cancer Registry, most patients are diagnosed at a late stage, reducing the effectiveness of treatment and survival rates. Improving early diagnosis with advanced imaging technology can have a meaningful impact on patient outcomes.

“Receiving HSA’s Pre-Market Approval is an important milestone for physicians and patients in Singapore,” said Benny Krauz, Vice President of Regulatory and Quality at Body Vision Medical. “Physicians will now be able to improve the success of their diagnostic bronchoscopy procedures with real-time three-dimensional imaging, which can lead to a meaningful stage shift in lung cancer diagnostics.”